Related Experiment Video
Updated: Oct 1, 2026
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Low-density DNA microarrays are versatile tools to screen for known mutations in hypertrophic cardiomyopathy
Stephan Waldmüller1, Petra Freund, Simon Mauch
1Max-Planck-Institute for Physiological and Clinical Research, Department of Experimental Cardiology, Bad Nauheim, Germany.
Insights
This study presents a novel oligonucleotide microarray for detecting known mutations in familial hypertrophic cardiomyopathy (HCM). This chip-based assay offers a feasible and potentially automated method for genetic testing of HCM patients.
Area of Science:
- Cardiovascular Genetics
- Molecular Diagnostics
- Biotechnology
Background:
- Familial hypertrophic cardiomyopathy (HCM) is a myocardial disorder caused by genetic mutations affecting heart muscle cell contractility.
- Current genetic testing for HCM is challenging due to mutations in at least eight different genes and the lack of affordable, high-throughput methods.
- Known mutations are recurrent in unrelated HCM families, suggesting pre-screening for these mutations is a viable strategy.
Purpose of the Study:
- To develop and validate an oligonucleotide probe array for the high-throughput detection of known mutations in familial hypertrophic cardiomyopathy.
- To assess the feasibility and robustness of a chip-based hybridization assay for genetic screening of HCM patients.
Main Methods:
- Development of a low-density oligonucleotide probe array immobilized on glass slides.
- The array was designed to detect 12 different heterozygous mutations, including single- and double-base exchanges, insertions, and deletions across four genes.
- Mutation detection utilized a CCD camera-based fluorescence biochip reader, with analysis of DNA hybridization.
Main Results:
- The oligonucleotide probe array successfully detected 12 known heterozygous mutations associated with familial hypertrophic cardiomyopathy.
- The assay demonstrated robustness, tolerating variations in mutation position, target DNA amount, and amplicon size (up to 800 bp).
- The technique allowed for screening of multiple exons within a single amplicon, indicating its efficiency.
Conclusions:
- Chip-based oligonucleotide hybridization is a feasible and robust method for detecting known familial hypertrophic cardiomyopathy mutations.
- This approach offers a simple, potentially automatable, and high-throughput solution for pre-screening HCM patients.
- Development of a comprehensive chip covering most known HCM mutations is considered feasible and clinically useful.
Abstract:
Familial hypertrophic cardiomyopathy (HCM or CMH) is a myocardial disorder caused by mutations that affect the contractile machinery of heart muscle cells. Genetic testing of HCM patients is hampered by the fact that mutations in at least eight different genes contribute to the disease. An affordable high-throughput mutation detection method is as yet not available. Since a significant number of mutations have been repeatedly found in unrelated families, we consider it feasible to pre-screen patients for known mutations, before more laborious techniques capable of detecting new mutations are applied. Here we demonstrate that the principle of hybridization of DNA to oligonucleotide probes immobilized on chips (glass slides) can be applied for this purpose. We have developed a low-density oligonucleotide probe array capable of detecting 12 different heterozygous mutations (in four different genes), among them single- and double-base exchanges, a single nucleotide insertion, and a trinucleotide deletion. The assay is simple and may be amenable to automation. Detection is achieved with a CCD camera-based fluorescence biochip reader. The technique turned out to be robust: Variations in either the relative position of a mutation, or the amount and size of target-DNA were compatible with mutation detection. Mutations could even be detected in amplicons as long as 800 bp, allowing the screening of more than one exon in one amplicon. Our data suggest that the development of a chip that covers all or most of known HCM-associated mutations is feasible and useful.
Related Concept Videos
02:34DNA Microarrays
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...